Novartis(US:NVS) Globenewswire·2025-12-12 12:00Core Viewpoint - Novartis has commenced construction on a new flagship manufacturing hub in North Carolina, which is part of a broader $23 billion investment in US infrastructure over the next five years, aimed at enhancing domestic production capabilities for key medicines [1][2][4]. Group 1: Investment and Job Creation - The North Carolina project will consist of a new facility in Morrisville and a new site in Durham, along with the expansion of an existing facility in Durham, expected to create 700 new jobs by 2030 and support over 3,000 indirect jobs in the Novartis US supply chain [2][5]. - This investment is a significant part of Novartis' strategy to strengthen its manufacturing and research network across the US, ensuring end-to-end manufacturing capabilities for its key medicines [4][10]. Group 2: Regulatory and R&D Developments - In 2025, Novartis achieved five FDA approvals across various therapeutic areas, reinforcing its commitment to innovation for US patients [9]. - The company is also expanding its R&D capabilities with plans for a new $1.1 billion biomedical research hub in San Diego, CA, complementing its existing research hub in Cambridge, MA [9]. Group 3: Strategic Importance of the Manufacturing Hub - The new manufacturing hub is expected to be operational by 2027-2028 and will serve as a central site for Novartis manufacturing in the US, enhancing the supply chain and supporting the delivery of medicines at scale [5][10]. - The establishment of this hub reflects Novartis' commitment to producing key medicines domestically, aligning with the broader goal of increasing national security in drug manufacturing [5][10].